Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Vanessa Al-Rawi, Thorsten Laeufer, Katrin Glocker, Yvonne Heneka and Alexandra Matzke-Ogi | ||||||||||||
Title | Abstract 4911: Allosteric inhibition of the Receptor Tyrosine Kinases c-MET, RON and VEGFR-2 via the co-receptor CD44v6 by the novel compound AMC303 | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/77/13_Supplement/4911.short | ||||||||||||
Abstract Text | Cancer Res 2017;77(13 Suppl):Abstract nr 4911 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AMC303 | AMC-303|AMC 303 | AMC303 is an allosteric inhibitor of CD44v6, the co-receptor of c-MET, RON, and VEGFR2, which may result in decreased cell invasion and migration, and tumor regression (Cancer Res 2017;77(13 Suppl):Abstract nr 4911). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|